Loading...
XSTOEGTX
Market cap215mUSD
Dec 23, Last price  
6.65SEK
1D
0.91%
1Q
51.14%
Jan 2017
-62.00%
IPO
-46.78%
Name

Egetis Therapeutics AB (publ)

Chart & Performance

D1W1MN
XSTO:EGTX chart
P/E
—
P/S
41.47
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
37.03%
Rev. gr., 5y
15.35%
Revenues
58m
+156.00%
002,66600000013,585,00028,211,00082,562,00040,662,00038,243,00022,500,00057,600,000
Net income
-327m
L+72.51%
-559,065-1,345,648-3,800,624-33,246,055-33,857,000-25,549,000-48,420,000-43,836,000-38,223,000-87,935,000-85,003,000-61,429,000-179,121,000-104,730,000-189,500,000-326,900,000
CFO
-278m
L+60.46%
-2,717,199-14,395,782-31,957,000-28,066,000-41,384,000-51,153,000-36,115,000-86,551,000-80,310,000-62,641,000-134,639,000-130,110,000-173,500,000-278,400,000
Earnings
Feb 20, 2025

Profile

Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
URL
https://www.egetis.com/
IPO date
Apr 07, 2011
Employees
23
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
57,600
156.00%
22,500
-41.17%
38,243
-5.95%
Cost of revenue
204,500
278,900
199,711
Unusual Expense (Income)
NOPBT
(146,900)
(256,400)
(161,468)
NOPBT Margin
Operating Taxes
100
(4,300)
188
Tax Rate
NOPAT
(147,000)
(252,100)
(161,656)
Net income
(326,900)
72.51%
(189,500)
80.94%
(104,730)
-41.53%
Dividends
Dividend yield
Proceeds from repurchase of equity
381,900
164,800
BB yield
-26.32%
-11.95%
Debt
Debt current
7,400
1,600
1,502
Long-term debt
110,000
3,800
6,802
Deferred revenue
Other long-term liabilities
5,100
4,400
410
Net debt
(186,700)
(123,100)
(136,446)
Cash flow
Cash from operating activities
(278,400)
(173,500)
(130,110)
CAPEX
(172)
Cash from investing activities
(100)
(1,700)
(5,957)
Cash from financing activities
458,900
155,700
(8,902)
FCF
(148,700)
(250,526)
(161,189)
Balance
Cash
303,300
127,700
143,965
Long term investments
800
800
785
Excess cash
301,220
127,375
142,838
Stockholders' equity
(1,234,400)
(922,200)
(735,799)
Invested Capital
1,898,100
1,435,500
1,267,399
ROIC
ROCE
EV
Common stock shares outstanding
260,011
194,238
179,906
Price
5.58
-21.41%
7.10
5.81%
6.71
-10.17%
Market cap
1,450,864
5.20%
1,379,091
14.24%
1,207,172
120.02%
EV
1,264,164
1,255,991
1,070,726
EBITDA
(143,300)
(253,700)
(159,013)
EV/EBITDA
Interest
4,100
100
188
Interest/NOPBT